研報掘金丨中原證券:長江證券基本面有望見底回升,維持“增持”評級
中原證券日前研報指出,長江證券(000783.SZ)上半年機構經紀業務受公募費改的影響偏大,合併口徑經紀業務淨收入短期波動有所加大,但淨收入總額仍處於中小券商前列,收入貢獻被動提高;計入其他債權投資的債券持倉規模同比減少、兩融規模隨市下降,導致公司利息淨收入降幅有所擴大,收入貢獻持穩。近年來公司權益自營持續拖累業績表現,在市場回暖後公司基本面有望見底回升。公司於5月15日發佈公吿,國務院國資委已同意湖北能源、三峽資本將所持有的15.6%股權轉讓給長江產業集團,湖北國資將成為公司第一大股東,關注後續股權轉讓進展。本次股權轉讓完成後,公司的區域優勢有望進一步強化。維持“增持”的投資評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.